Mankind Pharma, RDIF ink pact for Sputnik V sale in India
New Delhi: The Covid-19 vaccine, Sputnik V is now likely to be rolled out in India by Delhi-based Mankind Pharma apart from Dr Reddy's Laboratories, as the drugmaker has recently struck a deal with the Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund for sales and distribution of the drug.
According to a recent media report in Economic Times, the announcement to this effect would be made by next week.
On August 11, 2020, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world's first registered vaccine against COVID-19 based on the human adenoviral vectors platform.
In September, RDIF entered into a partnership with Dr Reddy's Laboratories to conduct clinical trials of the Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddy's regulatory approval in India.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.